Practical experience of managing patients with new coronavirus infection COVID-19 in hospital (preliminary results and guidelines)

The publication is dedicated to the guidelines based on the authors’ personal experience on diagnostics and treatment of the novel coronavirus infection COVID-19, and its complications. The most important recommendations are related to the issues of correct understanding of lung lesions under COVID-19 from the perspective of practicing physicians, and challenging questions of using antibacterial therapy were analyzed. It is very important to analyze if it is necessary to define two biomarkers of inflammatory response – S-reactive protein and procalcitonin. Internal data on the result of using systemic gluco-corticosteroids under COVID-19 were presented, and the recommendations on their use were given. 

1. Bassetti M. The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm. https://doi.org/10.1111/eci.13209. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13209.

2. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 6 (28.04.2020).

3. Canada.ca. 2019 novel coronavirus: Symptoms and treatment The official website of the Government of Canada URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirusinfection/symptoms.html.

4. CDC. 2019 Novel Coronavirus URL: https://www.cdc.gov/coronavirus/2019-ncov/index.html.

5. Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. DOI: 10.1016/S0140-6736(20)30211-7.

6. Huang C. et al. Cinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 DOI: 10.1016/S0140-6736(20)30183-5. [Epub ahead of print].

7. Guan et al. Clinical characteristics of 2019 novel coronavirus infection in China // N Engl J Med. 2020, Apr 30; 382 (18): 1708-1720.

8. Zhang J. et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics // Lancet Respir Med. 2020. DOI: 10.1016/S2213-2600(20)30071-0.

9. COVID-19: обсуждение спорных моментов, касающихся вызванных коронавирусом изменений в лёгких, и подходов к лечению. Информационное письмо МАСРМ. URL: http://www.antibiotic.ru/index.php?article=2959.

10. Fantini J., Scala C. D., Chahinian H., Yahi N. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection // Int J Antimicrob Agents. 2020, Apr 3: 105960. DOI: 10.1016/j.ijantimicag.2020.105960.

11. Molina J. M., Delaugerre C., Le Goff J., et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit With the Combination of Hydroxychloroquine and Azithromycin in Patients With Severe COVID-19 Infection // Med Mal Infect. 2020, Jun; 50 (4): 384. DOI: 10.1016/j.medmal.2020.03.006.

12. Critical Care COVID-19 Management Protocol. (updated 5-14-2020). URL: https://www.evms.edu/media/evms_public/departments/internal_medicine/Marik-Covid-Protocol-Summary.pdf.

13. Du B., Qiu H., Zhan X., et al. Pharmacotherapeutics for the New Coronavirus Pneumonia // Zhonghua Jie He He Hu Xi Za Zhi. 2020, Mar 12; 43 (3): 173-176. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.005.